Early signs of survival benefit raise optimism around a small biotech's ALS drug
Bio Pharma Dive
OCTOBER 16, 2020
Newly published data show that, after joining a clinical trial, patients who were given a drug from Amylyx Pharmaceutcials lived a median 6.5 months longer than those who didn't.
Let's personalize your content